Table 2.
Age group specific percentages of participants with hemagglutination inhibition antibody titers >1:40 for WHO-recommended influenza strains contained in trivalent study vaccines.
| TIV |
aTIV |
||||||
|---|---|---|---|---|---|---|---|
| 6 through | 12 through | 36 through | 6 through | 12 through | 36 through | ||
| 11 months | 35 months | 71 months | 11 months | 35 months | 71 months | ||
| HA dose (volume) | 15 μg | 15 μg | 15 μg | 7.5 μg + MF59 | 7.5μg + MF59 | 15 μg + MF59 | |
| (0.5 ml) | (0.5 ml) | (0.5 ml) | (0.25 ml) | (0.25 ml) | (0.5 ml) | ||
| N = 26 | N = 34 | N = 33 | N = 30 | N = 31 | N = 38 | ||
| A/California (H1N1) | |||||||
| HI Ab titer ≥40% | Baseline | 0.0% (0.0–13.2) | 5.9% (0.72–19.7) | 33.3% (18.0–51.8) | 6.7% (0.82–22.1) | 6.5% (0.79–21.4) | 52.6% (35.8–69.0) |
| (95% CI) | 28d post dose 1 | 3.8% (0.10–19.6) | 14.7% (5.0–31.1) | 63.6% (45.1–79.6) | 70.0% (50.6–85.3) | 87.1% (70.2–96.4) | 92.1% (78.6–98.3) |
| 28d post dose 2 | 73.1% (52.2–88.4) | 94.1% (80.3–99.3) | 97.0% (84.2–99.9) | 100.0% (88.4–100.0) | 100.0% (88.8–100.0) | 100.0% (90.8–100.0) | |
| Seroconversion | 28d post dose 1 | 3.8% (0.10–19.6) | 14.7% (5.0–31.1) | 63.6% (45.1–79.6) | 70.0% (50.6–85.3) | 87.1% (70.2–96.4) | 92.1% (78.6–98.3) |
| from baseline | 28d post dose 2 | 73.1% (52.2–88.4) | 94.1% (80.3–99.3) | 97.0% (84.2–99.9) | 100.0% (88.4–100.0) | 100.0% (88.8–100.0) | 94.7% (82.3–99.4) |
| A/Victoria (H3N2) | |||||||
| HI Ab titer ≥40% | Baseline | 23.1% (9.0–43.7) | 76.5% (58.8–89.3) | 75.8% (57.7–88.9) | 40.0% (22.7–59.4) | 58.1% (39.1–75.5) | 86.8% (71.9–95.6) |
| (95% CI) | 28d post dose 1 | 50.0% (29.9–70.1) | 94.1% (80.3–99.3) | 90.9% (75.7–98.1) | 83.3% (65.3–94.4) | 93.5% (78.6–99.2) | 100.0% (90.8–100.0) |
| 28d post dose 2 | 96.2% (80.4–99.9) | 100.0% (89.7–100.0) | 100.0% (89.4–100.0) | 100.0% (88.4–100.0) | 100.0% (88.8–100.0) | 100.0% (90.8–100.0) | |
| Seroconversion | 28d post dose 1 | 50.0% (29.9–70.1) | 91.2% (76.3–98.1) | 72.7% (54.5–86.7) | 83.3% (65.3–94.4) | 87.1% (70.2–96.4) | 97.4% (86.2–99.9) |
| from baseline | 28d post dose 2 | 100.0% (86.8–100.0) | 100.0% (89.7–100.0) | 87.9% (71.8–96.6) | 96.7% (82.8–99.9) | 96.8% (83.3–99.9) | 86.8% (71.9–95.6) |
| B/Wisconsin | |||||||
| (Yamagata lineage) | |||||||
| HI Ab titer ≥40% | Baseline | 26.9% (11.6–47.8) | 41.2% (24.7–59.3) | 51.5% (33.5–69.2) | 16.7% (5.6–34.7) | 38.7% (21.9–57.8) | 52.6% (35.8–69.0) |
| (95% CI) | 28d post dose 1 | 42.3% (23.4–63.1) | 55.9% (37.9–72.8) | 66.7% (48.2–82.0) | 63.3% (43.9–80.1) | 64.5% (45.4–80.8) | 76.3% (59.9–88.6) |
| 28d post dose 2 | 80.8% (60.7–93.5) | 97.1% (84.7–99.9) | 97.0% (84.2–99.9) | 100.0% (88.4–100.0) | 100.0% (88.8–100.0) | 100.0% (90.8–100.0) | |
| Seroconversion | 28d post dose 1 | 19.2% (6.6–39.4) | 35.3% (19.8–53.5) | 54.6% (36.4–71.9) | 50.0% (31.3–68.7) | 54.8% (36.0–72.7) | 55.3% (38.3–71.4) |
| from baseline | 28d post dose 2 | 57.7% (36.9–76.7) | 79.4% (62.1–91.3) | 78.8% (61.1–91.0) | 100.0% (88.4–100.0) | 90.3% (74.3–98.0) | 89.5% (75.2–97.1) |